Baxter's Aurora
This article was originally published in The Gray Sheet
Executive Summary
Home hemodialysis system debut forecast for later this year, Chief Financial Officer Brian Anderson reports at recent U.S. Bancorp Piper Jaffray health care conference in New York City. Competitors will include Aksys, which expects clearance via 510(k) by June for the PHD personal hemodialysis system (1"The Gray Sheet" Feb. 5, 2001, p. 11). Baxter's renal product pipeline for 2001 also includes a pediatric version of the HomeChoice peritoneal dialysis system and a polysulphone high flux dialyzer
You may also be interested in...
Aksys Projects $400 Mil. In PHD Hemodialysis System Revenues By 2006
Aksys expects PHD personal hemodialysis system revenues in the U.S. to reach approximately $400 mil. by 2006.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.